Free tool
Upcoming earnings calendar
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the US in the next 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
22 companies reporting in the next 90 days. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | 1M return | |
|---|---|---|---|---|---|
| Monday, Oct 26 · in 60 days · 1 company | |||||
| BMRN | BioMarin Pharmaceutical Inc. | Rare disease | $12.80B | +9.71% | |
| Wednesday, Oct 28 · in 62 days · 1 company | |||||
| BBIO | BridgeBio Pharma, Inc. | Rare disease | $15.85B | −4.42% | |
| Thursday, Oct 29 · in 63 days · 5 companies | |||||
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | Rare disease | $35.05B | −4.67% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | Rare disease | |||
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock. Looking for a name that isn't listed? Jump straight to it:
| $32.12B |
| −13.76% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | Rare disease | $31.87B | −20.91% |
| INSM | Insmed Incorporated | Rare disease | $27.07B | +18.29% |
| 0JAV.L | Insmed Incorporated | Rare disease | $12.89B | +0.69% |
| Monday, Nov 2 · in 67 days · 3 companies | |||||
| VX1.DE | Vertex Pharmaceuticals Incorporated | Rare disease | $140.77B | +10.56% | |
| VRTX | Vertex Pharmaceuticals Incorporated | Rare disease | $140.04B | +15.42% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | Rare disease | $112.52B | +1.12% | |
| Tuesday, Nov 3 · in 68 days · 1 company | |||||
| KYMR | Kymera Therapeutics, Inc. | Rare disease | $10.53B | +15.07% | |
| Wednesday, Nov 4 · in 69 days · 3 companies | |||||
| GOSS | Gossamer Bio, Inc. | Rare disease | $99.97M | +2.76% | |
| SCYX | SCYNEXIS, Inc. | Rare disease | $51.64M | +45.38% | |
| MCRB | Seres Therapeutics, Inc. | Rare disease | $46.81M | +3.09% | |
| Thursday, Nov 5 · in 70 days · 3 companies | |||||
| CYTK | Cytokinetics, Incorporated | Rare disease | $10.77B | −3.92% | |
| PTGX | Protagonist Therapeutics, Inc. | Rare disease | $10.01B | +11.09% | |
| ATYR | aTyr Pharma, Inc. | Rare disease | $55.91M | +16.33% | |
| Tuesday, Nov 10 · in 75 days · 1 company | |||||
| JSPR | Jasper Therapeutics, Inc. | Rare disease | $23.96M | +3.78% | |
| Thursday, Nov 12 · in 77 days · 4 companies | |||||
| SPRO | Spero Therapeutics, Inc. | Rare disease | $70.76M | +4.24% | |
| QNCX | Quince Therapeutics, Inc. | Rare disease | $34.05M | +73.28% | |
| TVRD | Tvardi Therapeutics, Inc. | Rare disease | $23.74M | −28.35% | |
| JAGX | Jaguar Health, Inc. | Rare disease | $4.78M | −7.51% | |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India). Reporting dates are public estimates and can shift.